From this point, the aim of the current work was to assess the effects of novel GPR119 agonist ZB-16 including the influence of the substance on the glucose utilization, insulin, and GLP-1 secretion and the morphology of pancreas during the chronic administration to the rats with streptozotocin–nicotinamide-induced diabetes. Here, GLP1R is linked to diabetes mellitus.